4-(ethylthio)-1-butanol | 18721-62-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-(ethylthio)-1-butanol
• 英文别名: 1-Butanol, 4-(ethylthio)-；4-ethylsulfanylbutan-1-ol
• CAS: 18721-62-5
• 化学式: C₆H₁₄OS
• mdl: MFCD12035400
• 分子量: 134.243
• InChiKey: XEIZVCOAFMXFCO-UHFFFAOYSA-N

物化性质

• 沸点：
  120 °C(Press: 19 Torr)
• 密度：
  0.9794 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(ethylthio)-1-butanol 在 氯化亚砜 、 氯仿 、 二甲胺 作用下， 生成 丁烷,1-氯-4-(乙硫基)-
  参考文献：
  名称：

  Bennett; Heathcoat; Mosses, Journal of the Chemical Society, 1929, p. 2570

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯丁醇 、 乙硫醇钠 以90%的产率得到4-(ethylthio)-1-butanol
  参考文献：
  名称：

  Robinson, Philip L.; Kelly, Jeffery W.; Slayton, A. Evans, Phosphorus and Sulfur and the Related Elements, 1987, vol. 31, p. 59 - 70

  摘要：

  DOI：

文献信息

• [EN] TREATMENT OF HELICOBACTER PYLORI INFECTIONS<br/>[FR] TRAITEMENT DES INFECTIONS À HELICOBACTER PYLORI
  申请人：EINSTEIN COLL MED

  公开号：WO2014025842A1

  公开（公告）日：2014-02-13

  Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5'-methylthioadenosine nucleosidase) to the subject.

  治疗幽门螺杆菌（H. pylori）感染的方法，特别是在患有消化性溃疡的患者中，包括向患者施用H. pylori MTAN（5'-甲硫腺苷核苷酸酶）抑制剂的方法。
• [EN] CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS<br/>[FR] COMPOSÉS D'ACIDE CARBOXYLIQUE DANS LE TRAITEMENT DU DIABÈTE SUCRÉ
  申请人：FUJIAN HAIXI PHARMACEUTICALS CO LTD

  公开号：WO2015024526A1

  公开（公告）日：2015-02-26

  The invention relates to compounds for increasing GPR40 recetpor activity and application thereof. These compounds include of a compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, isomers thereof, or produgs of the compounds mentioned above, or the mixture of any form above mentioned. The invention also relates to the use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity or for Insulin secretagogue.

  该发明涉及增加GPR40受体活性的化合物及其应用。这些化合物包括公式（I）的化合物，其药学上可接受的盐、溶剂化合物、异构体、上述化合物的前药，或上述任何形式的混合物。该发明还涉及将这些化合物用于制造用于治疗和/或预防糖尿病、肥胖或胰岛素分泌素的药物。
• Photochemical reactions of sulfide-containing alkyl phenylglyoxylates
  作者：Shengkui Hu、Douglas C. Neckers

  DOI：10.1016/s0040-4020(97)00420-1

  日期：1997.5

  yields. Cyclization occurred between the excited carbonyl group and the carbon a to the sulfur on the remote side. The more methylenes placed between the carbonyl group and the sulfide, the lower the yield of 3 while intermolecular hydrogen abstraction induced reductive dimerization and intramolecular Norrish Type II photolysis become competitive. The remote cyclization can be rationalized by a photoinduced

  乙硫基烷基苯乙醛酸酯（2）进行区域选择性光环化，以高收率产生多达13元的环噻唑（3）。在激发的羰基和碳a到远端的硫之间发生环化。在羰基和硫化物之间放置的亚甲基越多，3的收率越低分子间氢提取引起的还原二聚作用和分子内的Norrish II型光解作用具有竞争性。可以通过从硫原子到激发的羰基的光诱导电子转移，然后进行质子转移和随后的双自由基环化，使远程环化合理化。随着连接电子给体和受体的链变得更长和更柔韧，电子传输的速率常数增加。
• Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use
  申请人：Sankyo Company Limited

  公开号：EP0536936A1

  公开（公告）日：1993-04-14

  Compounds of formula (I): [in which: R¹, R² and R³ are the same or different and each represents a hydrogen atom, an optionally substituted alkanoyl group or an alkenylcarbonyl group, provided that at least one of R¹, R² and R³ represents an unsubstituted alkanoyl group having from 5 to 24 carbon atoms, said substituted alkanoyl group or said alkenylcarbonyl group; and one of R⁴ and R⁵ represents a hydrogen atom and the other represents a cyano group]; have valuable anti-tumour activity.

  式子（I）的化合物：[其中：R¹、R²和R³相同或不同，每个代表氢原子、可选取代的脂肪酰基团或烯基羰基团，前提是至少有一个R¹、R²和R³代表有5到24个碳原子的未取代脂肪酰基团，或者是所述取代的脂肪酰基团或所述烯基羰基团；R⁴和R⁵中的一个代表氢原子，另一个代表氰基]，具有有价值的抗肿瘤活性。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。